A Phase 2 interventional study of Romiplostim in Thrombocytopenia, MDS and Myelodysplastic Syndromes, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-16.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies testing romiplostim in Thrombocytopenia — 9 open to participants now, 9 under way, 3 of them phase 3. romiplostim · Thrombocytopenia.
Among the 41 studies testing romiplostim in Thrombocytopenia, this one is the 13th largest by enrollment, is one of 5 that started in 2006, is one of 20 in phase 2, and was the 8th registered.
484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.
Browse Thrombocytopenia studies →9 of the 41 studies testing romiplostim in Thrombocytopenia are open now, in 3 countries. Recruiting first, the newest first:
Nantes University Hospital · Sites in France
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
Anhui Provincial Hospital · Sites in China
Ages 18–75
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–75
Ain Shams University · Sites in Egypt
Ages 1–18
By country, each count listing its studies:
romiplostim: first FDA approval 2008 (NPLATE), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 24 · Phase 3 13 · Phase 4 1
First in 2002; this study’s year is marked. 5 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is above the median of 54 across 336 interventional studies indexed under Thrombocytopenia.
Median enrollment 62 across the 41 interventional studies. Of the 29 that completed or were terminated, 20 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 41 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
20 studies in Thrombocytopenia by Amgen: none open now, none under way, none of them phase 3. Of 19 finished, 17 (89%) have results posted.
Among the 20 studies in Thrombocytopenia by Amgen, this one is the 6th largest by enrollment of the 19 interventional ones that give a count, is one of 6 that started in 2006, is one of 6 in phase 2, and was the 7th registered.
Amgen’s Thrombocytopenia studies by the year they started, since 2002.
1 of the studies testing romiplostim in Thrombocytopenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06898983Anhui Provincial HospitalEfficacy and Safety Study of Romiplostim N01 for Cancer Treatment-induced Thrombocytopenia (CTIT) in the Treatment of Leukemia | 2027-01-31 |
Add it to your calendar (.ics) → With an account.
Among the 41 studies testing romiplostim in Thrombocytopenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 20 in Thrombocytopenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and tolerability of romiplostim in thrombocytopenic patients with low or Intermediate-1 risk MDS. In addition, the study will evaluate the platelet response to romiplostim.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort 1 in Part A, participants received romiplostim 300 µg subcutaneously once weekly for 3 weeks. Participants who completed Part A could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
Drug: Romiplostim
Cohort 2 in Part A, participants received romiplostim 700 µg subcutaneously once weekly for up to 3 weeks. Participants who completed Part A could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
Drug: Romiplostim
Cohort 3 in Part A, participants received romiplostim 1000 µg subcutaneously once weekly for up to 3 weeks. Participants who completed Part A could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
Drug: Romiplostim
Cohort 4 in Part A, participants received romiplostim 1500 µg subcutaneously once weekly for up to 3 weeks. Participants who completed Part A could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
Drug: Romiplostim
Part B participants received romiplostim 750 µg subcutaneously (SC) once weekly (QW) for 8 weeks. Participants who complete Part B could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
Drug: Romiplostim
Part B participants received romiplostim 750 µg subcutaneously every two weeks (Q2W) for 8 weeks. Participants who complete Part B could continue to receive injections of romiplostim for up to 1 year in the extension treatment phase.
Drug: Romiplostim
Part B participants received romiplostim 750 µg intravenously (IV) once every two weeks for 8 weeks. Participants who complete Part B could continue to receive romiplostim for up to 1 year in the extension treatment phase.
Drug: Romiplostim
Also known as: AMG 531, Nplate®
Part A: Number of Participants With Adverse Events
The number of participants experiencing one or more adverse events during the treatment phase or extension phase of Part A.
Time frame: Treatment period (4 weeks) plus treatment extension (1 year)
Part B: Number of Participants With Adverse Events
The number of participants experiencing one or more adverse events during the treatment phase or extension phase of Part B.
Time frame: Treatment period (8 weeks) plus treatment extension (1 year)
Part A: Number of Participants With a Complete or Major Platelet Response
Participants with a complete or major response during the treatment phase. A complete platelet response was defined as a platelet count ≥ 100 x 10\^9/L during the treatment phase. A major platelet response was defined as an increase in absolute platelet count of ≥ 30 x 10\^9/L for patients starting with \> 20 x 10\^9/L platelets, or an increase from ≤ 20 x 10\^9/L to \> 20 x 10\^9/L and by at least 100%. Any participant receiving rescue medication was considered a non-responder. Platelet transfusions were considered rescue medication.
Time frame: Treatment Period (4 weeks)
Part B: Number of Participants With a Complete or Major Platelet Response
Participants with a complete or major response during the treatment phase. A complete platelet response was defined as a platelet count ≥ 100 x 10\^9/L during the treatment phase. A major platelet response was defined as an increase in absolute platelet count of ≥ 30 x 10\^9/L for patients starting with \> 20 x 10\^9/L platelets, or an increase from ≤ 20 x 10\^9/L to \> 20 x 10\^9/L and by at least 100%. Any participant receiving rescue medication was considered a non-responder. Platelet transfusions were considered rescue medication.
Time frame: Treatment Period (8 weeks)
Part A: Number of Participants With a Platelet Response Per IWG Criteria
The number of participants with a platelet response according to the modified International Working Group (IWG) criteria. Response was defined as an absolute increase of ≥ 30 x 10\^9/L with Baseline platelet count \> 20 x 10\^9/L, or with a Baseline count ≤ 20 x 10\^9/L, increasing to above 20 x 10\^9/L and by at least 100% during the treatment or extension period and maintained for at least 8 consecutive weeks. Platelet transfusion was not considered a rescue medication but platelet counts ≤72 hours after platelet transfusion were excluded from the analysis.
Time frame: Treatment period (4 weeks) and extension period (52 weeks).
Part B: Number of Participants With a Platelet Response Per IWG
The number of participants with a platelet response according to the modified International Working Group (IWG) criteria. Response was defined as an absolute increase of ≥ 30 x 10\^9/L with Baseline platelet count \> 20 x 10\^9/L, or with a Baseline count ≤ 20 x 10\^9/L, increasing to above 20 x 10\^9/L and by at least 100% during the treatment or extension period and maintained for at least 8 consecutive weeks. Platelet transfusion was not considered a rescue medication but platelet counts ≤72 hours after platelet transfusion were excluded from the analysis.
Time frame: Treatment period (8 weeks) and extension period (52 weeks).
Part B: Peak Platelet Count
Peak platelet count (10\^9/L) during the treatment period.
Time frame: Treatment Period (8 weeks)
Part B: Time to First Platelet Response
Participants achieving first platelet response according to IWG criteria, by study week. Platelet response was defined as an absolute increase of ≥ 30 x 10\^9/L with Baseline platelet count \> 20 x 10\^9/L, or with a Baseline ≤ 20 x 10\^9/L increasing the platelet count to above 20 x 10\^9/L and by at least 100% for 8 consecutive weeks. Platelet counts obtained within 72 hours of platelet transfusion were not evaluable for platelet response.
Time frame: Treatment Period (8 weeks) and extension period (52 weeks).
Part B: Duration of Platelet Response
Duration of platelet response per IWG criteria (absolute increase of ≥ 30 x 10\^9/L with Baseline platelet count \> 20 x 10\^9/L, or with a Baseline ≤ 20 x 10\^9/L increasing the platelet count to above 20 x 10\^9/L and by at least 100% for 8 consecutive weeks).
Time frame: Treatment Period (8 weeks) and extension period (52 weeks)
Part B: Week 1 Cmax
Maximum observed serum concentration (Cmax) of romiplostim during Week 1
Time frame: Week 1
Part B: Week 1 Ctrough
Measured romiplostim concentration at the end of the week 1 dosing interval (Ctrough)
Time frame: Week 1
Part B: Week 1 AUC0-4
Area under the romiplostim concentration-time curve from time zero to the last time point with quantifiable concentration (AUC0-4) during Week 1
Time frame: Week 1
Part B: Week 7 Cmax
Maximum observed serum concentration (Cmax) of romiplostim during Week 7.
Time frame: Week 7
Part B: Week 7 Ctrough
Measured romiplostim concentration at the end of the Week 7 dosing interval (Ctrough)
Time frame: Week 7
Part B: Week 7 AUC0-4
Area under the romiplostim concentration-time curve from time zero to the last time point with quantifiable concentration (AUC0-4) during Week 7.
Time frame: Week 7
Part B: Week 1 Tmax
Time at which the maximum concentration of romiplostum was observed after subcutaneous administration during Week 1
Time frame: Week 1
Part B: Week 7 Tmax
Time at which the maximum concentration of romiplostum was observed after subcutaneous administration during Week 7
Time frame: Week 7
First Subject Enrolled: 15-Feb-2006 Last Subject Enrolled: 29-Feb-2008
| Milestone | Part A: 300 µg Romiplostim | Part A: 700 µg Romiplostim | Part A: 1000 µg Romiplostim | Part A: 1500 µg Romiplostim | Part B: 750 µg Romiplostim SC QW | Part B: 750 µg Romiplostim SC Q2W | Part B: 750 µg Romiplostim IV Q2W |
|---|---|---|---|---|---|---|---|
| Started | 6 | 11 | 11 | 16 | 11 | 12 | 5 |
| Completed | 6 | 11 | 11 | 14 | 8 | 11 | 3 |
| Not completed | 0 | 0 | 0 | 2 | 3 | 1 | 2 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Disease progression (to aml) | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Milestone | Part A: 300 µg Romiplostim | Part A: 700 µg Romiplostim | Part A: 1000 µg Romiplostim | Part A: 1500 µg Romiplostim | Part B: 750 µg Romiplostim SC QW | Part B: 750 µg Romiplostim SC Q2W | Part B: 750 µg Romiplostim IV Q2W |
|---|---|---|---|---|---|---|---|
| Started | 6 | 11 | 11 | 13 | 5 | 5 | 1 |
| Completed | 1 | 5 | 2 | 5 | 1 | 4 | 1 |
| Not completed | 5 | 6 | 9 | 8 | 4 | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 2 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 4 | 2 | 3 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 | 2 | 1 | 0 | 0 |
| Withdrew: Other | 0 | 2 | 4 | 2 | 1 | 0 | 0 |
| Withdrew: Disease progression (to aml) | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
Participants with a complete or major response during the treatment phase. A complete platelet response was defined as a platelet count ≥ 100 x 10\^9/L during the treatment phase. A major platelet response was defined as an increase in absolute platelet count of ≥ 30 x 10\^9/L for patients starting with \> 20 x 10\^9/L platelets, or an increase from ≤ 20 x 10\^9/L to \> 20 x 10\^9/L and by at least 100%. Any participant receiving rescue medication was considered a non-responder. Platelet transfusions were considered rescue medication.
| Participants | Part A: 300 µg Romiplostim | Part A: 700 µg Romiplostim | Part A: 1000 µg Romiplostim | Part A: 1500 µg Romiplostim |
|---|---|---|---|---|
| Part A: Number of Participants With a Complete or Major Platelet Response | 3 | 5 | 4 | 8 |
Participants with a complete or major response during the treatment phase. A complete platelet response was defined as a platelet count ≥ 100 x 10\^9/L during the treatment phase. A major platelet response was defined as an increase in absolute platelet count of ≥ 30 x 10\^9/L for patients starting with \> 20 x 10\^9/L platelets, or an increase from ≤ 20 x 10\^9/L to \> 20 x 10\^9/L and by at least 100%. Any participant receiving rescue medication was considered a non-responder. Platelet transfusions were considered rescue medication.
| Participants | Part B: 750 µg Romiplostim SC QW | Part B: 750 µg Romiplostim SC Q2W | Part B: 750 µg Romiplostim IV Q2W |
|---|---|---|---|
| Part B: Number of Participants With a Complete or Major Platelet Response | 5 | 8 | 2 |
The number of participants with a platelet response according to the modified International Working Group (IWG) criteria. Response was defined as an absolute increase of ≥ 30 x 10\^9/L with Baseline platelet count \> 20 x 10\^9/L, or with a Baseline count ≤ 20 x 10\^9/L, increasing to above 20 x 10\^9/L and by at least 100% during the treatment or extension period and maintained for at least 8 consecutive weeks. Platelet transfusion was not considered a rescue medication but platelet counts ≤72 hours after platelet transfusion were excluded from the analysis.
| Participants | Part A: 300 µg Romiplostim | Part A: 700 µg Romiplostim | Part A: 1000 µg Romiplostim | Part A: 1500 µg Romiplostim |
|---|---|---|---|---|
| Part A: Number of Participants With a Platelet Response Per IWG Criteria | 3 | 6 | 4 | 6 |
The number of participants with a platelet response according to the modified International Working Group (IWG) criteria. Response was defined as an absolute increase of ≥ 30 x 10\^9/L with Baseline platelet count \> 20 x 10\^9/L, or with a Baseline count ≤ 20 x 10\^9/L, increasing to above 20 x 10\^9/L and by at least 100% during the treatment or extension period and maintained for at least 8 consecutive weeks. Platelet transfusion was not considered a rescue medication but platelet counts ≤72 hours after platelet transfusion were excluded from the analysis.
| Participants | Part B: 750 µg Romiplostim SC QW | Part B: 750 µg Romiplostim SC Q2W | Part B: 750 µg Romiplostim IV Q2W |
|---|---|---|---|
| Part B: Number of Participants With a Platelet Response Per IWG | 2 | 4 | 1 |
Peak platelet count (10\^9/L) during the treatment period.
| 10^9/L | Part B: 750 µg Romiplostim SC QW | Part B: 750 µg Romiplostim SC Q2W | Part B: 750 µg Romiplostim IV Q2W |
|---|---|---|---|
| Part B: Peak Platelet Count | 100.0 (49.0 to 175.5) | 111.0 (58.0 to 453.0) | 83.0 (55.0 to 135.0) |
Participants achieving first platelet response according to IWG criteria, by study week. Platelet response was defined as an absolute increase of ≥ 30 x 10\^9/L with Baseline platelet count \> 20 x 10\^9/L, or with a Baseline ≤ 20 x 10\^9/L increasing the platelet count to above 20 x 10\^9/L and by at least 100% for 8 consecutive weeks. Platelet counts obtained within 72 hours of platelet transfusion were not evaluable for platelet response.
| Participants | Part B: 750 µg Romiplostim SC QW | Part B: 750 µg Romiplostim SC Q2W | Part B: 750 µg Romiplostim IV Q2W |
|---|---|---|---|
| Week 1 Day 3 | 0 | 1 | 0 |
| Week 2 | 2 | 1 | 1 |
| Week 3 | 0 | 1 | 0 |
| Week 4 | 0 | 0 | 0 |
| Week 5 or later | 0 | 1 | 0 |
| Not Observed | 6 | 7 | 3 |
Duration of platelet response per IWG criteria (absolute increase of ≥ 30 x 10\^9/L with Baseline platelet count \> 20 x 10\^9/L, or with a Baseline ≤ 20 x 10\^9/L increasing the platelet count to above 20 x 10\^9/L and by at least 100% for 8 consecutive weeks).
| Weeks | Part B: 750 µg Romiplostim SC QW | Part B: 750 µg Romiplostim SC Q2W | Part B: 750 µg Romiplostim IV Q2W |
|---|---|---|---|
| Part B: Duration of Platelet Response | 19.5 (8.0 to 31.0) | 9.0 (8.0 to 10.5) | 9.0 (9.0 to 9.0) |
Maximum observed serum concentration (Cmax) of romiplostim during Week 1
| pg/mL | Part B: 750 µg Romiplostim SC QW | Part B: 750 µg Romiplostim SC Q2W | Part B: 750 µg Romiplostim IV Q2W |
|---|---|---|---|
| Part B: Week 1 Cmax | 3660 ± 3070 | 3190 ± 2360 | 197000 ± 112000 |
Measured romiplostim concentration at the end of the week 1 dosing interval (Ctrough)
| pg/mL | Part B: 750 µg Romiplostim SC QW | Part B: 750 µg Romiplostim SC Q2W | Part B: 750 µg Romiplostim IV Q2W |
|---|---|---|---|
| Part B: Week 1 Ctrough | 171 ± 212 | 35.2 ± 31.5 | 96.5 ± 127 |
Area under the romiplostim concentration-time curve from time zero to the last time point with quantifiable concentration (AUC0-4) during Week 1
| hr*pg/mL | Part B: 750 µg Romiplostim SC QW | Part B: 750 µg Romiplostim SC Q2W | Part B: 750 µg Romiplostim IV Q2W |
|---|---|---|---|
| Part B: Week 1 AUC0-4 | 190000 ± 181000 | 182000 ± 111000 | 2030000 ± 838000 |
Maximum observed serum concentration (Cmax) of romiplostim during Week 7.
| pg/mL | Part B: 750 µg Romiplostim SC QW | Part B: 750 µg Romiplostim SC Q2W |
|---|---|---|
| Part B: Week 7 Cmax | 785 ± 906 | 357 ± 361 |
Measured romiplostim concentration at the end of the Week 7 dosing interval (Ctrough)
| pg/mL | Part B: 750 µg Romiplostim SC QW | Part B: 750 µg Romiplostim SC Q2W |
|---|---|---|
| Part B: Week 7 Ctrough | 54.6 ± 21.0 | 20.1 ± 1.98 |
Area under the romiplostim concentration-time curve from time zero to the last time point with quantifiable concentration (AUC0-4) during Week 7.
| hr*pg/mL | Part B: 750 µg Romiplostim SC QW | Part B: 750 µg Romiplostim SC Q2W |
|---|---|---|
| Part B: Week 7 AUC0-4 | 57100 ± 64300 | 35500 ± 36400 |
Time at which the maximum concentration of romiplostum was observed after subcutaneous administration during Week 1
| Hours | Part B: 750 µg Romiplostim SC QW | Part B: 750 µg Romiplostim SC Q2W |
|---|---|---|
| Part B: Week 1 Tmax | 24.0 (24 to 24) | 24.0 (24 to 24) |
Time at which the maximum concentration of romiplostum was observed after subcutaneous administration during Week 7
| Hours | Part B: 750 µg Romiplostim SC QW | Part B: 750 µg Romiplostim SC Q2W |
|---|---|---|
| Part B: Week 7 Tmax | 24.0 (2 to 120) | 24.0 (24 to 72) |
The number of participants experiencing one or more adverse events during the treatment phase or extension phase of Part A.
| Participants | Part A: 300 µg Romiplostim | Part A: 700 µg Romiplostim | Part A: 1000 µg Romiplostim | Part A: 1500 µg Romiplostim |
|---|---|---|---|---|
| Part A: Number of Participants With Adverse Events | 6 | 11 | 11 | 15 |
The number of participants experiencing one or more adverse events during the treatment phase or extension phase of Part B.
| Participants | Part B: 750 µg Romiplostim SC QW | Part B: 750 µg Romiplostim SC Q2W | Part B: 750 µg Romiplostim IV Q2W |
|---|---|---|---|
| Part B: Number of Participants With Adverse Events | 10 | 11 | 5 |
Collected over Every visit and up to 30 days after end of study (up to 64 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: 300 µg Romiplostim | — | 2/6 (33.3%) | 6/6 (100%) |
| Part A: 700 µg Romiplostim | — | 3/11 (27.3%) | 11/11 (100%) |
| Part A: 1000 µg Romiplostim | — | 2/11 (18.2%) | 11/11 (100%) |
| Part A: 1500 µg Romiplostim | — | 10/16 (62.5%) | 15/16 (93.8%) |
| Part B: 750 µg Romiplostim SC QW | — | 1/11 (9.1%) | 10/11 (90.9%) |
| Part B: 750 µg Romiplostim SC Q2W | — | 2/12 (16.7%) | 10/12 (83.3%) |
| Part B: 750 µg Romiplostim IV Q2W | — | 2/5 (40%) | 4/5 (80%) |
| Event | Part A: 300 µg Romiplostim | Part A: 700 µg Romiplostim | Part A: 1000 µg Romiplostim | Part A: 1500 µg Romiplostim | Part B: 750 µg Romiplostim SC QW | Part B: 750 µg Romiplostim SC Q2W | Part B: 750 µg Romiplostim IV Q2W |
|---|---|---|---|---|---|---|---|
| Cardiac arrestCardiac disorders | 0/6 | 0/11 | 0/11 | 0/16 | 0/11 | 0/12 | 1/5 |
| Coronary artery dissectionCardiac disorders | 0/6 | 0/11 | 0/11 | 0/16 | 0/11 | 0/12 | 1/5 |
| Rectal haemorrhageGastrointestinal disorders | 0/6 | 0/11 | 0/11 | 0/16 | 0/11 | 0/12 | 1/5 |
| HypersensitivityImmune system disorders | 0/6 | 0/11 | 0/11 | 0/16 | 0/11 | 0/12 | 1/5 |
| Subarachnoid haemorrhageNervous system disorders | 0/6 | 0/11 | 0/11 | 0/16 | 0/11 | 0/12 | 1/5 |
| Lobar pneumoniaInfections and infestations | 1/6 | 0/11 | 0/11 | 0/16 | 0/11 | 0/12 | 0/5 |
| PneumoniaInfections and infestations | 1/6 | 0/11 | 0/11 | 0/16 | 1/11 | 0/12 | 0/5 |
| FallInjury, poisoning and procedural complications | 1/6 | 0/11 | 0/11 | 0/16 | 0/11 | 0/12 | 0/5 |
| HyperkalaemiaMetabolism and nutrition disorders | 1/6 | 0/11 | 0/11 | 0/16 | 0/11 | 0/12 | 0/5 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 1/6 | 0/11 | 0/11 | 0/16 | 0/11 | 0/12 | 0/5 |
| Event | Part A: 300 µg Romiplostim | Part A: 700 µg Romiplostim | Part A: 1000 µg Romiplostim | Part A: 1500 µg Romiplostim | Part B: 750 µg Romiplostim SC QW | Part B: 750 µg Romiplostim SC Q2W | Part B: 750 µg Romiplostim IV Q2W |
|---|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 4/6 | 5/11 | 0/11 | 3/16 | 4/11 | 1/12 | 0/5 |
| DiarrhoeaGastrointestinal disorders | 3/6 | 1/11 | 2/11 | 5/16 | 1/11 | 0/12 | 0/5 |
| Oedema peripheralGeneral disorders | 3/6 | 2/11 | 1/11 | 2/16 | 1/11 | 1/12 | 0/5 |
| Back painMusculoskeletal and connective tissue disorders | 1/6 | 3/11 | 3/11 | 1/16 | 4/11 | 0/12 | 0/5 |
| HeadacheNervous system disorders | 1/6 | 3/11 | 2/11 | 3/16 | 4/11 | 1/12 | 0/5 |
| VomitingGastrointestinal disorders | 2/6 | 2/11 | 0/11 | 2/16 | 1/11 | 0/12 | 0/5 |
| Upper respiratory tract infectionInfections and infestations | 2/6 | 1/11 | 1/11 | 1/16 | 0/11 | 0/12 | 0/5 |
| ContusionInjury, poisoning and procedural complications | 2/6 | 1/11 | 1/11 | 3/16 | 2/11 | 0/12 | 0/5 |
| DizzinessNervous system disorders | 2/6 | 2/11 | 1/11 | 1/16 | 0/11 | 1/12 | 0/5 |
| HaematuriaRenal and urinary disorders | 2/6 | 1/11 | 0/11 | 0/16 | 0/11 | 0/12 | 0/5 |
| Age, Continuous(Years) | Part A: 300 µg Romiplostim | Part A: 700 µg Romiplostim | Part A: 1000 µg Romiplostim | Part A: 1500 µg Romiplostim | Part B: 750 µg Romiplostim SC QW | Part B: 750 µg Romiplostim SC Q2W | Part B: 750 µg Romiplostim IV Q2W | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 77.5 ± 3.3 | 68.2 ± 10.2 | 70.9 ± 14.2 | 68.9 ± 13.8 | 69.4 ± 6.3 | 72.1 ± 9.9 | 72.2 ± 4.3 | 70.7 ± 10.6 |
| Sex: Female, Male(Participants) | Part A: 300 µg Romiplostim | Part A: 700 µg Romiplostim | Part A: 1000 µg Romiplostim | Part A: 1500 µg Romiplostim | Part B: 750 µg Romiplostim SC QW | Part B: 750 µg Romiplostim SC Q2W | Part B: 750 µg Romiplostim IV Q2W | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 0 | 5 | 2 | 5 | 2 | 3 | 1 | 18 |
| Male | 6 | 6 | 9 | 11 | 9 | 9 | 4 | 54 |
| Race/Ethnicity, Customized(Participants) | Part A: 300 µg Romiplostim | Part A: 700 µg Romiplostim | Part A: 1000 µg Romiplostim | Part A: 1500 µg Romiplostim | Part B: 750 µg Romiplostim SC QW | Part B: 750 µg Romiplostim SC Q2W | Part B: 750 µg Romiplostim IV Q2W | Total |
|---|---|---|---|---|---|---|---|---|
| White or Caucasian | 5 | 11 | 9 | 14 | 10 | 10 | 4 | 63 |
| Black or African American | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 2 |
| Hispanic or Latino | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 2 |
| Asian | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 2 |
| Japanese | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Aborigine | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 3 |
No study locations are listed for this record.
The record gives a start of Feb 2006, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2010, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Romiplostim